Research & Development

Research & DevelopmentR&D Pipeline


       

 

Anti-cancer Immunotherapy (CB-IC-01 : Autologous Killer Cell)


   

 



    Next generation NK cell therapy, "AKC Immunotherapy"
    Proprietary high-level NK cell cultivation technique   
    Found anti-cancer efficacy in various solid cancers
    Currently IITs for Recurrent Glioblastoma and Recurrent Ovarian
      Cancer ongoing


    

 

Peripheral Blood Mononuclear Cell Isolation and Final Product Cryopreservation




 
CEO Message
Vision
History
Overseas Corporations
Affiliated Companies
Business Overview
Cord Blood Banking Business
Bio Insurance Business
CHAUM Business(Non-medical)
IT Business
Other Businesses
CHA Biotech R&D Center
R&D Pipeline
Current Status of Clinical Trials
Patent Grants (Korea/Overseas)
Scientific Publications
Corporate Filings
Stock Information
IR Presentations